The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were genotyped in a recent study to detect HSD3B1 variance and to determine 2-y freedom from castration-resistant prostate cancer as well as overall survival. The results of this study identified HSD3B1 as a possible biomarker that can be used to predict response to therapy in patients with metastatic disease.

中文翻译：

---

检查HSD3B1作为可能的生物标记物，以检测可能在ADT上进展的前列腺癌患者。

前列腺癌广泛性疾病的化学激素治疗与雄激素消融随机试验（CHAARTED）是一项随机III期临床试验，评估了接受或不接受多西他赛去势的转移性前列腺癌男性的结局。来自该试验的患者在最近的一项研究中进行了基因分型，以检测HSD3B1变异并确定2年无去势抵抗性前列腺癌以及总生存期。这项研究的结果确定了HSD3B1是可能的生物标志物，可用于预测转移性疾病患者对治疗的反应。